Michele Kohli

1.6k total citations
31 papers, 1.2k citations indexed

About

Michele Kohli is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Michele Kohli has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 8 papers in Infectious Diseases and 7 papers in Health. Recurrent topics in Michele Kohli's work include SARS-CoV-2 and COVID-19 Research (8 papers), Vaccine Coverage and Hesitancy (7 papers) and Hepatitis B Virus Studies (6 papers). Michele Kohli is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (8 papers), Vaccine Coverage and Hesitancy (7 papers) and Hepatitis B Virus Studies (6 papers). Michele Kohli collaborates with scholars based in United States, Canada and United Kingdom. Michele Kohli's co-authors include Milton C. Weinstein, Eduardo L. Franco, Daniel Grima, Thomas C. Wright, S. J. Goldie, F. Xavier Bosch, Michael Maschio, Sue J. Goldie, Cheryl Attard and Gordana Atanackovic and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, American Journal of Obstetrics and Gynecology and British Journal of Cancer.

In The Last Decade

Michele Kohli

29 papers receiving 1.1k citations

Peers

Michele Kohli
Patrick Zuber Switzerland
Sarah Mbaeyi United States
Nathalie Largeron France
Roberta Pastore Philippines
Kim Knudsen Denmark
Danielle Moulia United States
Muki Shey South Africa
Vanessa Rémy France
S. J. Goldie United States
Musa Sekikubo Uganda
Patrick Zuber Switzerland
Michele Kohli
Citations per year, relative to Michele Kohli Michele Kohli (= 1×) peers Patrick Zuber

Countries citing papers authored by Michele Kohli

Since Specialization
Citations

This map shows the geographic impact of Michele Kohli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Kohli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Kohli more than expected).

Fields of papers citing papers by Michele Kohli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Kohli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Kohli. The network helps show where Michele Kohli may publish in the future.

Co-authorship network of co-authors of Michele Kohli

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Kohli. A scholar is included among the top collaborators of Michele Kohli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Kohli. Michele Kohli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kohli, Michele, et al.. (2026). Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States. Journal of Medical Economics. 29(1). 574–593.
2.
Kohli, Michele, et al.. (2025). The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada. Journal of Medical Economics. 28(1). 1440–1450. 2 indexed citations
3.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2024). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom. Journal of Medical Economics. 27(1). 1359–1372. 2 indexed citations
4.
Joshi, Keya, Ekkehard Beck, Michael Maschio, et al.. (2024). The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines. 12(4). 434–434. 1 indexed citations
5.
Kohli, Michele, et al.. (2024). Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine. Vaccine. 42(9). 2282–2289. 3 indexed citations
6.
Davido, Benjamin, Ekkehard Beck, Clarisse Demont, et al.. (2024). Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France. Human Vaccines & Immunotherapeutics. 20(1). 2423474–2423474. 1 indexed citations
7.
Joshi, Keya, Stefan Scholz, Michael Maschio, et al.. (2023). Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. Journal of Medical Economics. 27(1). 39–50. 9 indexed citations
8.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2023). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. Journal of Medical Economics. 26(1). 1532–1545. 16 indexed citations
9.
Maschio, Michael, et al.. (2022). An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom. Vaccines. 10(4). 599–599. 4 indexed citations
10.
11.
Maschio, Michael, Michele Kohli, Simron Singh, et al.. (2020). A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics. 38(6). 607–618. 3 indexed citations
12.
Kohli, Michele, Raymond Farkouh, Michael Maschio, et al.. (2015). Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion. Health Affairs. 34(7). 1234–1240. 6 indexed citations
13.
14.
Kohli, Michele, Cheryl Attard, Annette Lam, et al.. (2006). Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada. PharmacoEconomics. 24(8). 815–830. 18 indexed citations
15.
Kohli, Michele, Nicole Ferko, Eduardo L. Franco, et al.. (2006). Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. British Journal of Cancer. 96(1). 143–150. 92 indexed citations
16.
Shehata, Nadine, Michele Kohli, & Allan S. Detsky. (2004). The cost‐effectiveness of screening blood donors for malaria by PCR. Transfusion. 44(2). 217–228. 26 indexed citations
17.
Goldie, S. J., Michele Kohli, Daniel Grima, et al.. (2004). Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. JNCI Journal of the National Cancer Institute. 96(8). 604–615. 410 indexed citations
18.
Kohli, Michele, et al.. (2003). A Risk Index for Sternal Surgical Wound Infection After Cardiovascular Surgery. Infection Control and Hospital Epidemiology. 24(1). 17–25. 49 indexed citations
19.
Goldie, Sue J., Daniel Grima, Michele Kohli, et al.. (2003). A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine. International Journal of Cancer. 106(6). 896–904. 171 indexed citations
20.
Attard, Cheryl, Michele Kohli, Suzanne Coleman, et al.. (2002). The burden of illness of severe nausea and vomiting of pregnancy in the United States. American Journal of Obstetrics and Gynecology. 186(5). S220–S227. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Zuber Breakdown of academic impact, for papers by Sarah Mbaeyi Breakdown of academic impact, for papers by Nathalie Largeron Breakdown of academic impact, for papers by Roberta Pastore Breakdown of academic impact, for papers by Kim Knudsen Breakdown of academic impact, for papers by Danielle Moulia Breakdown of academic impact, for papers by Muki Shey Breakdown of academic impact, for papers by Vanessa Rémy Breakdown of academic impact, for papers by S. J. Goldie Breakdown of academic impact, for papers by Musa Sekikubo
Rankless by CCL
2026